3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Interventions
Cyclophosphamide
62
Rituximab
47
fludarabine
35
fludarabine phosphate
27
obinutuzumab
17
Mycophenolic Acid
16
ibrutinib
15
Whole-Body Irradiation
15
Lenalidomide
15
Specimen Handling
14
Prednisone
14
venetoclax
13
pirtobrutinib
13
Etoposide
13
Doxorubicin
13
pembrolizumab
12
Tacrolimus
12
Magnetic Resonance Spectroscopy
11
Granulocyte Colony-Stimulating Factor
11
Filgrastim
11
Biopsy
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
Melphalan
10
X-Rays
9
Bendamustine Hydrochloride
9
polatuzumab vedotin
8
glofitamab
8
acalabrutinib
8
Immunotherapy, Adoptive
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
CLR1404
×
1 year
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled